Skip to main content

Baclofen News

FDA Approves Fleqsuvy (baclofen oral suspension) for the Treatment of Spasticity

WOBURN, MA, February 7, 2022 – Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, focused on developing innovative products to meet the unique needs of patients with u...

FDA Approves Lyvispah (baclofen) Oral Granules for the Treatment of Spasticity

ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Dec. 7, 2021 /PRNewswire/ – Saol Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved Saol's Lyvispah (baclofen)...

FDA Approves Movement Disorder Drug from CNS Therapeutics: Gablofen (Baclofen Injection) for the Treatment of Severe Spasticity

ST. PAUL, Minn.--(BUSINESS WIRE)--Nov 23, 2010 - Today, CNS Therapeutics announced the FDA approval of Gablofen (baclofen injection) for use in the management of severe spasticity, giving healthcare...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Alcohol Withdrawal, Muscle Spasm, Neuralgia, Temporomandibular Joint Disorder, Periodic Limb Movement Disorder, Migraine Prevention, Migraine Prophylaxis, Muscle Twitching, Huntington's Disease, Trigeminal Neuralgia

Baclofen patient information at Drugs.com